Spine BioPharma, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Nov 21, 2024--

Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced that Chief Executive Officer Marc Viscogliosi will present at the Piper Sandler 36 th Annual Healthcare Conference on Thursday, December 5th at 12:30 p.m. E.T. in New York.

About SB-01 For Injection

SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by almost every tissue and cell type, is stored in abundance in the extracellular matrix, and possesses suppressive and stimulatory signaling pathways. In many diseases, there are high concentrations of TGF-Beta that result in a spectrum of negative downstream effects including inflammation, fibrosis, neoinnervation, hyperexcitability of nerves and cell proliferation. SB-01 modulates TGF-Beta concentration, without eliminating it, mitigating the negative downstream effects.

About Spine BioPharma

Spine BioPharma is committed to developing non-opiate, non-surgical treatments that will reduce pain, restore function, and slow or stop pathological disease progression. Spine BioPharma’s lead candidate, SB-01 For Injection, is a first-in-class treatment of DDD, offering potential clinical benefits of pain relief, restoration of function, and prevention of disease progression. To learn more about Spine BioPharma, visit www.spinebiopharma.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20241121248220/en/

CONTACT: Corporate Inquiries:

Jason Gallagher

Chief Commercial Officer & Chief Operating Officer

Spine Biopharma, Inc.

212-583-9700

jgallagher@spinebiopharma.comMedia Inquiries:

Sasha Damouni Ellis

Damouni Group LLC

sasha@damounigroup.com

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Spine BioPharma, Inc.

Copyright Business Wire 2024.